The text starts here.

News Release

FOR IMMEDIATE RELEASE
March 16, 2005

Eisai Receives Zonegran(R) Marketing Authorization
Granted by European Commission

Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) announced today that its U.K. subsidiary Eisai Ltd. (Headquarters: London, Managing Director: Paul Hooper) obtained marketing authorization approval of Zonegran(R) hard capsules (zonisamide), an anti-epileptic drug for the adjunctive therapy of partial seizures in adults, from the European Commission on March 10 (U.K. time).

In April 2004, Eisai obtained manufacturing, developing and marketing rights for Zonegran(R) in the U.S. and Europe from Elan Corporation, plc. Based on this, Eisai Ltd. succeeded a Marketing Authorization Application through the European Union's Centralized Procedure from Elan. In December 2004, Eisai Ltd. received a positive opinion for Zonegran(R) from the Committee For Medicinal Products for Human Use, the scientific body of the European Medicines Agency. Consequently, European Commission has granted marketing authorization approval for Zonegran(R).

Major characteristics of Zonegran(R) are that it has a wide anti-seizure spectrum and its drug-drug interactions with other anti-epileptic drugs are minimal. Zonegran(R) was approved and launched in March 2000 in the U.S. for adjunctive therapy in the treatment of partial seizures in adults with epilepsy. Eisai Inc., a subsidiary in the U.S., has been marketing the product since the end of April 2004. In Japan, the product was approved in 1989 and is marketed by Dainippon Pharmaceutical Co., Ltd. with the brand name Excegran(R).

Based on the receipt of this marketing authorization, Eisai will strengthen its neurology product pipeline and aim at expanding business opportunities in Europe in order to fulfil patients' needs and contribute to further improve benefits with drug treatment.


Contacts:

Corporate Communications Department
Eisai Co., Ltd.
81-3-3817-5120

[Excerpt of European Commission approval for Zonegran(R) follow]


[European Commission approval for Zonegran(R)]
Product name : Zonegran(R) hard capsules
Generic name : zonisamide
Pharmaceutical Forms and Strength : Capsules 25mg, 50mg, 100mg
Applied Indication: Adjunctive therapy in the treatment of adult patients with partial seizures, with or without secondary generalisation
Dosage and Administration: Once or twice daily p.o., 300-500mg/day normally